These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20697509)

  • 1. Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence.
    Younus J; Verma S; Franek J; Coakley N;
    Curr Oncol; 2010 Aug; 17(4):4-10. PubMed ID: 20697509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
    Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR; Leggas M
    Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
    Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
    Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H
    Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST).
    Rutkowski P; Bylina E; Lugowska I; Teterycz P; Klimczak A; Streb J; Czarnecka AM; Osuch C
    J Geriatr Oncol; 2018 Sep; 9(5):520-525. PubMed ID: 29602734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
    Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib.
    Cassier PA; Dufresne A; Arifi S; El Sayadi H; Ray-Coquard I; Bringuier PP; Scoazec JY; Alberti L; Blay JY
    Curr Gastroenterol Rep; 2008 Dec; 10(6):555-61. PubMed ID: 19006610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
    Demetri GD; van Oosterom AT; Garrett CR; Blackstein ME; Shah MH; Verweij J; McArthur G; Judson IR; Heinrich MC; Morgan JA; Desai J; Fletcher CD; George S; Bello CL; Huang X; Baum CM; Casali PG
    Lancet; 2006 Oct; 368(9544):1329-38. PubMed ID: 17046465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
    Patel S
    Cancer Treat Rev; 2012 Aug; 38(5):467-72. PubMed ID: 22035971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
    Reichardt P; Kang YK; Rutkowski P; Schuette J; Rosen LS; Seddon B; Yalcin S; Gelderblom H; Williams CC; Fumagalli E; Biasco G; Hurwitz HI; Kaiser PE; Fly K; Matczak E; Chen L; Lechuga MJ; Demetri GD
    Cancer; 2015 May; 121(9):1405-13. PubMed ID: 25641662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
    Liu X; Jiang WZ; Guan GX; Chen ZF; Chi P; Lu HS
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):221-5. PubMed ID: 23536339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
    Paz-Ares L; García del Muro X; Grande E; González P; Brosa M; Díaz S
    Clin Transl Oncol; 2008 Dec; 10(12):831-9. PubMed ID: 19068454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.
    Pilotte AP
    Curr Med Res Opin; 2015; 31(7):1363-76. PubMed ID: 25912466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the treatment of gastrointestinal stromal tumours.
    Judson I; Demetri G
    Ann Oncol; 2007 Sep; 18 Suppl 10():x20-4. PubMed ID: 17761719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST).
    Le Tourneau C; Raymond E; Faivre S
    Ther Clin Risk Manag; 2007 Jun; 3(2):341-8. PubMed ID: 18360643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD; Huse DM
    J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New paradigms in gastrointestinal stromal tumour management.
    Blay JY
    Ann Oncol; 2009 May; 20 Suppl 1():i18-24. PubMed ID: 19430004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical management of tyrosine kinase inhibitor-associated side effects in GIST.
    Joensuu H; Trent JC; Reichardt P
    Cancer Treat Rev; 2011 Feb; 37(1):75-88. PubMed ID: 20570050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.